Table of Contents Author Guidelines Submit a Manuscript
International Journal of Biomedical Imaging
Volume 2016, Article ID 7462014, 17 pages
http://dx.doi.org/10.1155/2016/7462014
Review Article

Insight into the Molecular Imaging of Alzheimer’s Disease

1Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida 201303, India
2Amity Institute of Biotechnology, Amity University Uttar Pradesh, Room No. 312, J3 Block, III Floor, Noida 201303, India

Received 30 September 2015; Accepted 16 December 2015

Academic Editor: Jyh-Cheng Chen

Copyright © 2016 Abishek Arora and Neeta Bhagat. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. P. Chapman, S. M. Williams, T. W. Strine, R. F. Anda, and M. J. Moore, “Dementia and its implications for public health,” Preventing Chronic Disease, vol. 3, no. 2, article A34, 2006. View at Google Scholar · View at Scopus
  2. D. C. Mash, D. D. Flynn, and L. T. Potter, “Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation,” Science, vol. 228, no. 4703, pp. 1115–1117, 1985. View at Publisher · View at Google Scholar · View at Scopus
  3. J. D. Gazewood, D. R. Richards, and K. Clebak, “Parkinson disease: an update,” American Family Physician, vol. 87, no. 4, pp. 267–273, 2013. View at Google Scholar · View at Scopus
  4. J. Massano, “Cognitive impairment and dementia—an update,” Frontiers in Neurology, vol. 3, article 153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Kljajevic, “Overestimating the effects of healthy aging,” Frontiers in Aging Neuroscience, vol. 7, article 164, 2015. View at Publisher · View at Google Scholar
  6. B. Frost and M. I. Diamond, “Prion-like mechanisms in neurodegenerative diseases,” Nature Reviews Neuroscience, vol. 11, no. 3, pp. 155–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. F. M. M. Lu and Z. Yuan, “PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases,” Quantitative Imaging in Medicine and Surgery, vol. 5, no. 3, pp. 433–447, 2015. View at Publisher · View at Google Scholar
  8. J. F. Jiménez Bonilla and J. M. Carril Carril, “Molecular neuroimaging in degenerative dementias,” Revista Espanola de Medicina Nuclear e Imagen Molecular, vol. 32, no. 5, pp. 301–309, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. P. A. Apurva, P. M. Bipin, and P. M. Kirti, “Role of PET scan in clinical practice,” Gujarat Medical Journal, vol. 68, no. 2, pp. 19–22, 2013. View at Google Scholar
  10. R. Weissleder and U. Mahmood, “Molecular imaging,” Radiology, vol. 219, no. 2, pp. 316–333, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Kim, O. D. Howes, and S. Kapur, “Molecular imaging as a guide for the treatment of central nervous system disorders,” Dialogues in Clinical Neuroscience, vol. 15, no. 3, pp. 315–328, 2013. View at Google Scholar · View at Scopus
  12. S. P. Mueller, J. F. Polak, M. F. Kijewski, and B. L. Holman, “Collimator selection for SPECT brain imaging: the advantage of high resolution,” Journal of Nuclear Medicine, vol. 27, no. 11, pp. 1729–1738, 1986. View at Google Scholar · View at Scopus
  13. L. Jiang, Y. Tu, H. Shi, and Z. Cheng, “PET probes beyond 18F-FDG,” Journal of Biomedical Research, vol. 28, no. 6, pp. 435–446, 2014. View at Google Scholar
  14. W. Mier and D. Mier, “Advantages in functional imaging of the brain,” Frontiers in Human Neuroscience, vol. 9, p. 249, 2015. View at Publisher · View at Google Scholar
  15. T. Varghese, R. Sheelakumari, J. S. James, and P. S. Mathuranath, “A review of neuroimaging biomarkers of Alzheimer’s disease,” Neurology Asia, vol. 18, no. 3, pp. 239–248, 2013. View at Google Scholar · View at Scopus
  16. K. Blennow, M. J. de Leon, and H. Zetterberg, “Alzheimer’s disease,” The Lancet, vol. 368, no. 9533, pp. 387–403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. Alzheimer’s Association, “2010 Alzheimer’s disease facts and figures,” Alzheimer’s and Dementia, vol. 6, no. 2, pp. 158–194, 2010. View at Publisher · View at Google Scholar
  18. W. T. Hu, A. Chen-Plotkin, S. E. Arnold et al., “Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment,” Acta Neuropathologica, vol. 119, no. 6, pp. 669–678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Devi and H. K. Anandatheerthavarada, “Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer’s and Parkinson’s diseases,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1802, no. 1, pp. 11–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Mancuso, G. Scapagnini, D. Currò et al., “Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders,” Frontiers in Bioscience, vol. 12, no. 3, pp. 1107–1123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. H. W. Querfurth and F. M. LaFerla, “Alzheimer’s disease,” The New England Journal of Medicine, vol. 362, no. 4, pp. 329–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Davidsson, A. Westman-Brinkmalm, C. L. Nilsson et al., “Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients,” NeuroReport, vol. 13, no. 5, pp. 611–615, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Korolainen, T. A. Nyman, P. Nyyssönen, E. S. Hartikainen, and T. Pirttilä, “Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease,” Clinical Chemistry, vol. 53, no. 4, pp. 657–665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Zetterberg, U. Rüetschi, E. Portelius et al., “Clinical proteomics in neurodegenerative disorders,” Acta Neurologica Scandinavica, vol. 118, no. 1, pp. 1–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Sihlbom, P. Davidsson, M. Sjögren, L.-O. Wahlund, and C. L. Nilsson, “Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer’s disease patients and healthy individuals,” Neurochemical Research, vol. 33, no. 7, pp. 1332–1340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Puchades, S. F. Hansson, C. L. Nilsson, N. Andreasen, K. Blennow, and P. Davidsson, “Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease,” Molecular Brain Research, vol. 118, no. 1-2, pp. 140–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Hesse, C. L. Nilsson, K. Blennow, and P. Davidsson, “Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry,” Electrophoresis, vol. 22, no. 9, pp. 1834–1837, 2001. View at Google Scholar · View at Scopus
  28. E. Tarkowski, K. Blennow, A. Wallin, and A. Tarkowski, “Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia,” Journal of Clinical Immunology, vol. 19, no. 4, pp. 223–230, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Blasko, W. Lederer, H. Oberbauer et al., “Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias,” Dementia and Geriatric Cognitive Disorders, vol. 21, no. 1, pp. 9–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Galimberti, N. Schoonenboom, P. Scheltens et al., “Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease,” Archives of Neurology, vol. 63, no. 4, pp. 538–543, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Gómez-Tortosa, I. Gonzalo, S. Fanjul et al., “Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease,” Archives of Neurology, vol. 60, no. 9, pp. 1218–1222, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Rota, G. Bellone, P. Rocca, B. Bergamasco, G. Emanuelli, and P. Ferrero, “Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients,” Neurological Sciences, vol. 27, no. 1, pp. 33–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. R. M. Evans, S. Hui, A. Perkins, D. K. Lahiri, J. Poirier, and M. R. Farlow, “Cholesterol and APOE genotype interact to influence Alzheimer disease progression,” Neurology, vol. 62, no. 10, pp. 1869–1871, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. M.-K. K. Sun, J. Hongpaisan, and D. L. Alkon, “Postischemic PKC activation rescues retrograde and anterograde long-term memory,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14676–14680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. J. de Barry, C. M. Liégeois, and A. Janoshazi, “Protein kinase C as a peripheral biomarker for Alzheimer’s disease,” Experimental Gerontology, vol. 45, no. 1, pp. 64–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Isagawa, H. Mukai, K. Oishi et al., “Dual effects of PKNα and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3β,” Biochemical and Biophysical Research Communications, vol. 273, no. 1, pp. 209–212, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Zetterberg, K. Blennow, and E. Hanse, “Amyloid β and APP as biomarkers for Alzheimer’s disease,” Experimental Gerontology, vol. 45, no. 1, pp. 23–29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Zetterberg, U. Andreasson, O. Hansson et al., “Elevated cerebrospinal fluid BACE1 activity in incipient alzheimer disease,” Archives of Neurology, vol. 65, no. 8, pp. 1102–1107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. A. Hardy and G. A. Higgins, “Alzheimer’s disease: the amyloid cascade hypothesis,” Science, vol. 256, no. 5054, pp. 184–185, 1992. View at Publisher · View at Google Scholar · View at Scopus
  40. T. L. Spires-Jones, W. H. Stoothoff, A. de Calignon, P. B. Jones, and B. T. Hyman, “Tau pathophysiology in neurodegeneration: a tangled issue,” Trends in Neurosciences, vol. 32, no. 3, pp. 150–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. A. Korolainen, T. A. Nyman, T. Aittokallio, and T. Pirttilä, “An update on clinical proteomics in Alzheimer’s research,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1386–1414, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Davinelli, M. Intrieri, C. Russo et al., “The “Alzheimer’s disease signature’: potential perspectives for novel biomarkers,” Immunity and Ageing, vol. 8, article 7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Dassati, A. Waldner, and R. Schweigreiter, “Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain,” Neurobiology of Aging, vol. 35, no. 7, pp. 1632–1642, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Lorente-Cebrián, A. G. G. Costa, S. Navas-Carretero et al., “An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases,” Journal of Physiology and Biochemistry, vol. 71, no. 2, pp. 341–349, 2015. View at Google Scholar
  45. X. Li, K. S. Montine, C. D. Keene, and T. J. Montine, “Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia,” The FASEB Journal, vol. 29, no. 5, pp. 1754–1762, 2015. View at Publisher · View at Google Scholar
  46. L. K. Ferreira and G. F. Busatto, “Neuroimaging in Alzheimer’s disease: current role in clinical practice and potential future applications,” Clinics, vol. 66, supplement 1, pp. 19–24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. R. C. Barber, “Biomarkers for early detection of Alzheimer disease,” Journal of the American Osteopathic Association, vol. 110, no. 9, pp. S10–S15, 2010. View at Google Scholar · View at Scopus
  48. L. Zhang, R. C.-C. Chang, L.-W. W. Chu, and H. K.-F. Mak, “Current neuroimaging techniques in Alzheimer’s disease and applications in animal models,” American Journal of Nuclear Medicine and Molecular Imaging, vol. 2, no. 3, pp. 386–404, 2012. View at Google Scholar
  49. K. J. Anstey, R. Eramudugolla, D. E. Hosking, N. T. Lautenschlager, and R. A. Dixon, “Bridging the translation gap: from dementia risk assessment to advice on risk reduction,” Journal of Prevention of Alzheimer’s Disease, vol. 2, no. 3, pp. 189–198, 2015. View at Google Scholar
  50. T. L. Spires-Jones and B. Hyman, “The intersection of amyloid β and tau at synapses in Alzheimer’s disease,” Neuron, vol. 82, no. 4, pp. 756–771, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Tabaton, X. Zhu, G. Perry, M. A. Smith, and L. Giliberto, “Signaling effect of amyloid-β42 on the processing of AβPP,” Experimental Neurology, vol. 221, no. 1, pp. 18–25, 2010. View at Publisher · View at Google Scholar
  52. W. Qin, L. Ho, J. Wang, E. Peskind, and G. M. Pasinetti, “S100A7, a novel Alzheimer’s disease biomarker with non-amyloidogenic α-secretase activity acts via selective promotion of ADAM-10,” PLoS ONE, vol. 4, no. 1, Article ID e4183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. P. L. Ross, Y. N. Huang, J. N. Marchese et al., “Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents,” Molecular and Cellular Proteomics, vol. 3, no. 12, pp. 1154–1169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Thompson, J. Schäfer, K. Kuhn et al., “Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS,” Analytical Chemistry, vol. 75, no. 8, pp. 1895–1904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. S. P. Gygi, B. Rist, S. A. Gerber, F. Turecek, M. H. Gelb, and R. Aebersold, “Quantitative analysis of complex protein mixtures using isotope-coded affinity tags,” Nature Biotechnology, vol. 17, no. 10, pp. 994–999, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Schmidt, J. Kellermann, and F. Lottspeich, “A novel strategy for quantitative proteomics using isotope-coded protein labels,” Proteomics, vol. 5, no. 1, pp. 4–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Tian, D. Liu, W. Xiang et al., “Analyses of the similarity and difference of global gene expression profiles in cortex regions of three neurodegenerative diseases: sporadic Creutzfeldt-Jakob disease (sCJD), fatal familial insomnia (FFI), and Alzheimer’s disease (AD),” Molecular Neurobiology, vol. 50, no. 2, pp. 473–481, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. G. M. McKhann, D. S. Knopman, H. Chertkow et al., “The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimer’s & Dementia, vol. 7, no. 3, pp. 263–269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Benadiba, G. Luurtsema, L. Wichert-Ana, C. A. Buchpigel, and G. B. Filho, “New molecular targets for PET and SPECT imaging in neurodegenerative diseases,” Revista Brasileira de Psiquiatria, vol. 34, no. 2, pp. S125–S148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Shim, M. J. Ly, and S. K. Tighe, “Brain imaging in the differential diagnosis of young-onset dementias,” Psychiatric Clinics of North America, vol. 38, no. 2, pp. 281–294, 2015. View at Publisher · View at Google Scholar
  61. M. E. Phelps, “Positron emission tomography provides molecular imaging of biological processes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 9226–9233, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Dann, D. Christman, J. Fowler, B. MacGregor, and A. Wolf, “Metabolic mapping of functional activity in human subjects with the [18F] fluorodeoxyglucose technique,” Science, vol. 212, no. 4495, pp. 678–680, 1981. View at Google Scholar
  63. K. Strijckmans, “The isochronous cyclotron: principles and recent developments,” Computerized Medical Imaging and Graphics, vol. 25, no. 2, pp. 69–78, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Halldin, B. Gulyás, O. Langer, and L. Farde, “Brain radioligands—state of the art and new trends,” Quarterly Journal of Nuclear Medicine, vol. 45, no. 2, pp. 139–152, 2001. View at Google Scholar · View at Scopus
  65. D. W. Townsend, “Dual-modality imaging: combining anatomy and function,” Journal of Nuclear Medicine, vol. 49, no. 6, pp. 938–955, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. J. M. Kofler, D. D. Cody, and R. L. Morin, “CT protocol review and optimization,” Journal of the American College of Radiology, vol. 11, no. 3, pp. 267–270, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Laruelle, M. Slifstein, and Y. Huang, “Positron emission tomography: imaging and quantification of neurotransporter availability,” Methods, vol. 27, no. 3, pp. 287–299, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Baert, Encyclopedia of Diagnostic Imaging, Springer, Berlin, Germany, 2008.
  69. I. Buvat, S. Laffont, J. Le Cloirec, P. Bourguet, and R. Di Paola, “Importance of the choice of the collimator for the detection of small lesions in scintimammography: a phantom study,” Physics in Medicine and Biology, vol. 46, no. 5, pp. 1343–1355, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Palumbo, T. Buresta, S. Nuvoli et al., “SPECT and PET serve as molecular imaging techniques and in Vivo biomarkers for brain metastases,” International Journal of Molecular Sciences, vol. 15, no. 6, pp. 9878–9893, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. S. L. Pimlott and A. Sutherland, “Molecular tracers for the PET and SPECT imaging of disease,” Chemical Society Reviews, vol. 40, no. 1, pp. 149–162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. V. L. Villemagne, M. T. Fodero-Tavoletti, K. E. Pike, R. Cappai, C. L. Masters, and C. C. Rowe, “The ART of loss: aβ imaging in the evaluation of Alzheimer’s disease and other dementias,” Molecular Neurobiology, vol. 38, no. 1, pp. 1–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Laruelle, M. Slifstein, and Y. Huang, “Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography,” Molecular Imaging & Biology, vol. 5, no. 6, pp. 363–375, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. V. W. Pike, “PET radiotracers: crossing the blood-brain barrier and surviving metabolism,” Trends in Pharmacological Sciences, vol. 30, no. 8, pp. 431–440, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. W. M. Pardridge, “Drug and gene delivery to the brain: the vascular route,” Neuron, vol. 36, no. 4, pp. 555–558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. J. E. Maggio, E. R. Stimson, J. R. Ghilardi et al., “Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5462–5466, 1992. View at Publisher · View at Google Scholar · View at Scopus
  77. R. P. Friedland, R. E. Majocha, J. M. Reno, L. R. Lyle, and C. A. Marotta, “Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer’s disease,” Molecular Neurobiology, vol. 9, no. 1–3, pp. 107–113, 1994. View at Publisher · View at Google Scholar · View at Scopus
  78. H. J. Lee, Y. Zhang, C. Zhu, K. Duff, and W. M. Pardridge, “Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical,” Journal of Cerebral Blood Flow Metabolism, vol. 22, no. 2, pp. 223–231, 2002. View at Google Scholar
  79. C. A. Mathis, Y. Wang, D. P. Holt, G.-F. F. Huang, M. L. Debnath, and W. E. Klunk, “Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents,” Journal of Medicinal Chemistry, vol. 46, no. 13, pp. 2740–2754, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. Z.-P. P. Zhuang, M.-P. P. Kung, A. Wilson et al., “Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting β-amyloid plaques in the brain,” Journal of Medicinal Chemistry, vol. 46, no. 2, pp. 237–243, 2003. View at Publisher · View at Google Scholar
  81. H. Engler, A. F. Santillo, S. X. Wang et al., “In vivo amyloid imaging with PET in frontotemporal dementia,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 100–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. G. D. Rabinovici, H. J. Rosen, A. Alkalay et al., “Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD,” Neurology, vol. 77, no. 23, pp. 2034–2042, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. V. L. Villemagne, K. Ong, R. S. Mulligan et al., “Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias,” Journal of Nuclear Medicine, vol. 52, no. 8, pp. 1210–1217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. W. E. Klunk, H. Engler, A. Nordberg et al., “Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B,” Annals of Neurology, vol. 55, no. 3, pp. 306–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. B. J. Bacskai, G. A. Hickey, J. Skoch et al., “Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12462–12467, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. C. C. Rowe, S. Ng, U. Ackermann et al., “Imaging β-amyloid burden in aging and dementia,” Neurology, vol. 68, no. 20, pp. 1718–1725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. C. C. Rowe, K. A. Ellis, M. Rimajova et al., “Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging,” Neurobiology of Aging, vol. 31, no. 8, pp. 1275–1283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Forsberg, H. Engler, O. Almkvist et al., “PET imaging of amyloid deposition in patients with mild cognitive impairment,” Neurobiology of Aging, vol. 29, no. 10, pp. 1456–1465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Edison, C. C. Rowe, J. O. Rinne et al., “Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 12, pp. 1331–1338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. M. A. Mintun, G. N. Larossa, Y. I. Sheline et al., “[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease,” Neurology, vol. 67, no. 3, pp. 446–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. N. S. Mason, C. A. Mathis, and W. E. Klunk, “Positron emission tomography radioligands for in vivo imaging of Aβ plaques,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 56, no. 3-4, pp. 89–95, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. A. E. Johnson, F. Jeppsson, J. Sandell et al., “AZD2184: a radioligand for sensitive detection of β-amyloid deposits,” Journal of Neurochemistry, vol. 108, no. 5, pp. 1177–1186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Nyberg, M. E. Jönhagen, Z. Cselényi et al., “Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 11, pp. 1859–1863, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Nordberg, “PET imaging of amyloid in Alzheimer’s disease,” The Lancet Neurology, vol. 3, no. 9, pp. 519–527, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. K. Shoghi-Jadid, G. W. Small, E. D. Agdeppa et al., “Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with alzheimer disease,” The American Journal of Geriatric Psychiatry, vol. 10, no. 1, pp. 24–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. P. W. Thompson, L. Ye, J. L. Morgenstern et al., “Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies,” Journal of Neurochemistry, vol. 109, no. 2, pp. 623–630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. E. D. Agdeppa, V. Kepe, K. Shoghi-Jadid et al., “In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer’s disease patient: a case study,” Journal of Nuclear Medicine, vol. 42, no. 5, p. 65, 2001. View at Google Scholar
  98. L. M. Smid, V. Kepe, H. V. Vinters et al., “Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging,” Journal of Alzheimer’s Disease, vol. 36, no. 2, pp. 261–274, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. G. W. Small, E. D. Agdeppa, V. Kepe, N. Satyamurthy, S.-C. Huang, and J. R. Barrio, “In vivo brain imaging of tangle burden in humans,” Journal of Molecular Neuroscience, vol. 19, no. 3, pp. 321–327, 2002. View at Google Scholar · View at Scopus
  100. H. Barthel and O. Sabri, “Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET,” Journal of Alzheimer’s Disease, vol. 26, no. 3, pp. 117–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. S. R. Choi, G. Golding, Z. Zhuang et al., “Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain,” Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1887–1894, 2009. View at Google Scholar
  102. D. F. Wong, P. B. Rosenberg, Y. Zhou et al., “In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18),” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 913–920, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. C. M. Clark, J. A. Schneider, B. J. Bedell et al., “Use of florbetapir-PET for imaging β-amyloid pathology,” Journal of the American Medical Association, vol. 305, no. 3, pp. 275–283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. C. C. Rowe, U. Ackerman, W. Browne et al., “Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism,” The Lancet Neurology, vol. 7, no. 2, pp. 129–135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Shokouhi, D. Claassen, and W. Riddle, “Imaging brain metabolism and pathology in Alzheimer’s disease with positron emission tomography,” Journal of Alzheimer’s Disease & Parkinsonism, vol. 4, no. 2, article 143, 2014. View at Publisher · View at Google Scholar
  106. N. Nelissen, K. Van Laere, L. Thurfjell et al., “Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease,” Journal of Nuclear Medicine, vol. 50, no. 8, pp. 1251–1259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. R. Vandenberghe, K. Adamczuk, P. Dupont, K. V. Laere, and G. Chételat, “Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer’s disease,” NeuroImage: Clinical, vol. 2, no. 1, pp. 497–511, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. C. C. Rowe and V. L. Villemagne, “Brain amyloid imaging,” Journal of Nuclear Medicine, vol. 52, no. 11, pp. 1733–1740, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. Z. Cselényi, M. E. Jönhagen, A. Forsberg et al., “Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand,” Journal of Nuclear Medicine, vol. 53, no. 3, pp. 415–424, 2012. View at Google Scholar
  110. A. Juréus, B.-M. M. Swahn, J. Sandell et al., “Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand,” Journal of Neurochemistry, vol. 114, no. 3, pp. 784–794, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. Y. Kudo, N. Okamura, S. Furumoto et al., “2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 553–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. Y. Kudo, “Development of amyloid imaging PET probes for an early diagnosis of Alzheimer’s disease,” Minimally Invasive Therapy and Allied Technologies, vol. 15, no. 4, pp. 209–213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Ono, A. Wilson, J. Nobrega et al., “11C-labeled stilbene derivatives as Aβ-aggregate-specific PET imaging agents for Alzheimer’s disease,” Nuclear Medicine and Biology, vol. 30, no. 6, pp. 565–571, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. W. E. Klunk, H. Engler, A. Nordberg et al., “Imaging the pathology of Alzheimer’s disease: amyloid-imaging with positron emission tomography,” Neuroimaging Clinics of North America, vol. 13, no. 4, pp. 781–789, 2003. View at Publisher · View at Google Scholar · View at Scopus
  115. N. P. L. G. Verhoeff, A. A. Wilson, S. Takeshita et al., “In-vivo imaging of Alzheimer disease β-amyloid with [11C]SB-13 PET,” American Journal of Geriatric Psychiatry, vol. 12, no. 6, pp. 584–595, 2004. View at Google Scholar · View at Scopus
  116. M. C. Hong, Y. K. Kim, J. Y. Choi et al., “Synthesis and evaluation of stilbene derivatives as a potential imaging agent of amyloid plaques,” Bioorganic and Medicinal Chemistry, vol. 18, no. 22, pp. 7724–7730, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. K. R. Eun and X. Chen, “Development of Alzheimer’s disease imaging agents for clinical studies,” Frontiers in Bioscience, vol. 13, no. 2, pp. 777–789, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Wu, V. W. Pike, and Y. Wang, “Amyloid imaging: from benchtop to bedside,” Current Topics in Developmental Biology, vol. 70, pp. 171–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. M.-P. Kung, C. Hou, Z.-P. Zhuang, D. Skovronsky, and H. F. Kung, “Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer’s disease,” Brain Research, vol. 1025, no. 1-2, pp. 98–105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. F. Hernández and J. Avila, “Tauopathies,” Cellular and Molecular Life Sciences, vol. 64, no. 17, pp. 2219–2233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  121. K. Arima, “Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies,” Neuropathology, vol. 26, no. 5, pp. 475–483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. P. J. Muchowski, “Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones?” Neuron, vol. 35, no. 1, pp. 9–12, 2002. View at Publisher · View at Google Scholar · View at Scopus
  123. M. G. Spillantini and M. Goedert, “Tau pathology and neurodegeneration,” The Lancet Neurology, vol. 12, no. 6, pp. 609–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. N. S. Honson, R. L. Johnson, W. Huang, J. Inglese, C. P. Austin, and J. Kuret, “Differentiating Alzheimer disease-associated aggregates with small molecules,” Neurobiology of Disease, vol. 28, no. 3, pp. 251–260, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. K. N. Schafer, S. Kim, A. Matzavinos, and J. Kuret, “Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer’s disease: a simulation study,” NeuroImage, vol. 60, no. 3, pp. 1724–1733, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. A. Taghavi, S. Nasir, M. Pickhardt et al., “N′-benzylidene-benzohydrazides as novel and selective tau-PHF ligands,” Journal of Alzheimer’s Disease, vol. 27, no. 4, pp. 835–843, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. S. J. Kemp, L. J. Storey, J. Storey, and J. Rickard, “Ligands for aggregated tau molecules,” US Patent, 2014.
  128. V. L. Villemagne and N. Okamura, “In vivo tau imaging: obstacles and progress,” Alzheimer’s & Dementia, vol. 10, no. 3, supplement, pp. S254–S264, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. M. T. Fodero-Tavoletti, N. Okamura, S. Furumoto et al., “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease,” Brain, vol. 134, part 4, pp. 1089–1100, 2011. View at Google Scholar
  130. R. Harada, N. Okamura, S. Furumoto, T. Tago et al., “Comparison of the binding characteristics of [18F] THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 1, pp. 125–132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. V. L. Villemagne, S. Furumoto, M. T. Fodero-Tavoletti et al., “In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 5, pp. 816–826, 2014. View at Publisher · View at Google Scholar · View at Scopus
  132. M. T. Fodero-Tavoletti, S. Furumoto, L. Taylor et al., “Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non Alzheimer’s disease tauopathies,” Acta Veterinaria Scandinavica, vol. 6, article 11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. N. Okamura, S. Furumoto, R. Harada et al., “Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease,” Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1420–1427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. E. R. Zimmer, A. Leuzy, S. Gauthier, and P. Rosa-Neto, “Developments in tau PET imaging,” The Canadian Journal of Neurological Sciences, vol. 41, no. 05, pp. 547–553, 2014. View at Publisher · View at Google Scholar
  135. N. Okamura, S. Furumoto, M. T. Fodero-Tavoletti et al., “Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET,” Brain, vol. 137, no. 6, pp. 1762–1771, 2014. View at Publisher · View at Google Scholar · View at Scopus
  136. Y. Li, W. Tsui, H. Rusinek et al., “Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease,” Journal of Nuclear Medicine, vol. 56, no. 2, pp. 270–273, 2015. View at Publisher · View at Google Scholar · View at Scopus
  137. W. Zhang, J. Arteaga, D. K. Cashion et al., “A highly selective and specific PET tracer for imaging of tau pathologies,” Journal of Alzheimer’s Disease, vol. 31, no. 3, pp. 601–612, 2012. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Förster, T. Grimmer, I. Miederer et al., “Regional expansion of hypometabolism in Alzheimer’s disease follows amyloid deposition with temporal delay,” Biological Psychiatry, vol. 71, no. 9, pp. 792–797, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. D. T. Chien, S. Bahri, A. K. Szardenings et al., “Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807,” Journal of Alzheimer’s Disease, vol. 34, no. 2, pp. 457–468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Mintun, A. Schwarz, A. Joshi et al., “Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer’s disease,” Alzheimer’s & Dementia, vol. 9, no. 4, p. P842, 2013. View at Publisher · View at Google Scholar
  141. D. T. Chien, A. K. Szardenings, S. Bahri et al., “Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808,” Journal of Alzheimer’s Disease, vol. 38, no. 1, pp. 171–184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Maruyama, H. Shimada, T. Suhara et al., “Imaging of tau pathology in a tauopathy mouse model and in alzheimer patients compared to normal controls,” Neuron, vol. 79, no. 6, pp. 1094–1108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  143. G. W. Small, V. Kepe, L. M. Ercoli et al., “PET of brain amyloid and tau in mild cognitive impairment,” The New England Journal of Medicine, vol. 355, no. 25, pp. 2652–2663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  144. J. Stefaniak and J. O’Brien, “Imaging of neuroinflammation in dementia: a review,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 87, pp. 21–28, 2016. View at Publisher · View at Google Scholar
  145. V. Pizza, A. Agresta, C. W. D’Acunto, M. Festa, and A. Capasso, “Neuroinflammation and ageing: current theories and an overview of the data,” Reviews on Recent Clinical Trials, vol. 6, no. 3, pp. 189–203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. R. M. Ransohoff and J. El Khoury, “Microglia in health and disease,” Cold Spring Harbor Perspectives in Biology, 2015. View at Publisher · View at Google Scholar
  147. D. G. Walker and L. F. F. Lue, “Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains,” Alzheimer’s Research & Therapy, vol. 7, no. 1, p. 56, 2015. View at Publisher · View at Google Scholar
  148. Z. Su, F. Roncaroli, P. F. Durrenberger et al., “The 18-kDa mitochondrial translocator protein in human gliomas: an 11C- (R)PK11195 PET imaging and neuropathology study,” Journal of Nuclear Medicine, vol. 56, no. 4, pp. 512–517, 2015. View at Publisher · View at Google Scholar
  149. P. Gut, M. Zweckstetter, and R. B. Banati, “Lost in translocation: the functions of the 18-kD translocator protein,” Trends in Endocrinology & Metabolism, vol. 26, no. 7, pp. 349–356, 2015. View at Publisher · View at Google Scholar
  150. M.-K. K. Chen and T. R. R. Guilarte, “Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair,” Pharmacology and Therapeutics, vol. 118, no. 1, pp. 1–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Cagnin, D. J. Brooks, A. M. Kennedy et al., “In-vivo measurement of activated microglia in dementia,” The Lancet, vol. 358, no. 9280, pp. 461–467, 2001. View at Publisher · View at Google Scholar · View at Scopus
  152. S. Chalon, C. Pellevoisin, S. Bodard, M.-P. Vilar, J.-C. Besnard, and D. Guilloteau, “Iodinated PK 11195 as an ex vivo marker of neuronal injury in the lesioned rat brain,” Synapse, vol. 24, no. 4, pp. 334–339, 1996. View at Publisher · View at Google Scholar · View at Scopus
  153. J. J. Versijpt, F. Dumont, K. J. Van Laere et al., “Assessment of neuroinflammation and microglial activation in Alzheimer’s disease with radiolabelled PK11195 and single photon emission computed tomography: a pilot study,” European Neurology, vol. 50, no. 1, pp. 39–47, 2003. View at Publisher · View at Google Scholar · View at Scopus
  154. S. Venneti, C. A. Wiley, and J. Kofler, “Imaging microglial activation during neuroinflammation and Alzheimer’s disease,” Journal of Neuroimmune Pharmacology, vol. 4, no. 2, pp. 227–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. A. S. C. Ching, B. Kuhnast, A. Damont, D. Roeda, B. Tavitian, and F. Dollé, “Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases,” Insights into Imaging, vol. 3, no. 1, pp. 111–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  156. H. Boutin, F. Chauveau, C. Thominiaux et al., “11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 573–581, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. H. Boutin, C. Prenant, R. Maroy et al., “[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats,” PLoS ONE, vol. 8, no. 2, Article ID e56441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  158. N. Van Camp, R. Boisgard, B. Kuhnast et al., “In vivo imaging of neuroinflammation: a comparative study between [18F]PBR111, [11C]CLINME and [11C]PK11195 in an acute rodent model,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 5, pp. 962–972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. G. Abourbeh, B. Thézé, R. Maroy et al., “Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [18F]DPA-714,” The Journal of Neuroscience, vol. 32, no. 17, pp. 5728–5736, 2012. View at Publisher · View at Google Scholar
  160. D. Tang, M. R. Hight, E. T. McKinley et al., “Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2- 18F-fluoroethoxy) phenyl)-5,7- dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide,” Journal of Nuclear Medicine, vol. 53, no. 2, pp. 287–294, 2012. View at Publisher · View at Google Scholar · View at Scopus
  161. N. Arlicot, A. Katsifis, L. Garreau et al., “Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 12, pp. 2203–2211, 2008. View at Publisher · View at Google Scholar
  162. F. Mattner, D. L. Bandin, M. Staykova et al., “Evaluation of [123I]-CLINDE as a potent SPECT radiotracer to assess the degree of astroglia activation in cuprizone-induced neuroinflammation,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 8, pp. 1516–1528, 2011. View at Publisher · View at Google Scholar · View at Scopus
  163. I. López-González, E. Aso, M. Carmona et al., “Neuroinflammatory gene regulation, mitochondrial function, oxidative stress, and brain lipid modifications with disease progression in tau P301S transgenic mice as a model of frontotemporal lobar degeneration-tau,” Journal of Neuropathology & Experimental Neurology, vol. 74, no. 10, pp. 975–999, 2015. View at Publisher · View at Google Scholar
  164. J. A. García-Sevilla, P. V. Escribá, and J. Guimón, “Imidazoline receptors and human brain disorders,” Annals of the New York Academy of Sciences, vol. 881, pp. 392–409, 1999. View at Publisher · View at Google Scholar · View at Scopus
  165. S. F. Carter, M. Schöll, O. Almkvist et al., “Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG,” Journal of Nuclear Medicine, vol. 53, no. 1, pp. 37–46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  166. A. F. Santillo, J. P. Gambini, L. Lannfelt et al., “In vivo imaging of astrocytosis in Alzheimer’s disease: an 11C-L-deuteriodeprenyl and PIB PET study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 12, pp. 2202–2208, 2011. View at Publisher · View at Google Scholar · View at Scopus
  167. K. Kawamura, Y. Kimura, J. Yui et al., “PET study using [11C]FTIMD with ultra-high specific activity to evaluate I2-imidazoline receptors binding in rat brains,” Nuclear Medicine and Biology, vol. 39, no. 2, pp. 199–206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  168. M. Wang, L. Xu, M. Gao, K. D. Miller, G. W. Sledge, and Q. H. H. Zheng, “[11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C,” Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 6, pp. 1649–1653, 2011. View at Google Scholar
  169. M.-K. K. Sun and D. L. Alkon, “The ‘memory kinases’: roles of PKC isoforms in signal processing and memory formation,” Progress in Molecular Biology and Translational Science, vol. 122, pp. 31–59, 2014. View at Publisher · View at Google Scholar · View at Scopus
  170. C. Wu, C. Wang, D. C. Popescu et al., “A novel PET marker for in vivo quantification of myelination,” Bioorganic & Medicinal Chemistry, vol. 18, no. 24, pp. 8592–8599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. M. Doubrovin, J. T. Che, I. Serganova et al., “Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging,” Molecular Imaging, vol. 11, no. 1, pp. 67–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  172. C. Chiu, M. C. Miller, R. Monahan, D. P. Osgood, E. G. Stopa, and G. D. Silverberg, “P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer’s disease: preliminary observations,” Neurobiology of Aging, vol. 36, no. 9, pp. 2475–2482, 2015. View at Publisher · View at Google Scholar
  173. G. Luurtsema, J. Verbeek, M. Lubberink et al., “Carbon-11 labeled tracers for in vivo imaging P-glycoprotein function: kinetics, advantages and disadvantages,” Current Topics in Medicinal Chemistry, vol. 10, no. 17, pp. 1820–1833, 2010. View at Publisher · View at Google Scholar · View at Scopus
  174. G. Esposito, G. Giovacchini, J.-S. S. Liow et al., “Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET,” Journal of Nuclear Medicine, vol. 49, no. 9, pp. 1414–1421, 2008. View at Publisher · View at Google Scholar · View at Scopus
  175. M. Singh, “Essential fatty acids, DHA and human brain,” Indian Journal of Pediatrics, vol. 72, no. 3, pp. 239–242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  176. S. I. Rapoport, E. Ramadan, and M. Basselin, “Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission,” Prostaglandins& Other Lipid Mediators, vol. 96, no. 1–4, pp. 109–113, 2011. View at Publisher · View at Google Scholar · View at Scopus
  177. J. A. Conquer, M. C. Tierney, J. Zecevic, W. J. Bettger, and R. H. Fisher, “Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment,” Lipids, vol. 35, no. 12, pp. 1305–1312, 2000. View at Publisher · View at Google Scholar · View at Scopus